[go: up one dir, main page]

FI941837A - Uusia sytokiinejä - Google Patents

Uusia sytokiinejä Download PDF

Info

Publication number
FI941837A
FI941837A FI941837A FI941837A FI941837A FI 941837 A FI941837 A FI 941837A FI 941837 A FI941837 A FI 941837A FI 941837 A FI941837 A FI 941837A FI 941837 A FI941837 A FI 941837A
Authority
FI
Finland
Prior art keywords
new cytokines
cytokines
new
immunogen
disclosed
Prior art date
Application number
FI941837A
Other languages
English (en)
Swedish (sv)
Other versions
FI116850B (fi
FI941837A0 (fi
Inventor
Richard J Armitage
William C Fanslow
Melanie K Spriggs
Subhashini Srinivasan
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27120174&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI941837(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of FI941837A0 publication Critical patent/FI941837A0/fi
Publication of FI941837A publication Critical patent/FI941837A/fi
Application granted granted Critical
Publication of FI116850B publication Critical patent/FI116850B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FI941837A 1991-10-25 1994-04-20 CD40-L-polypeptidiä koodaavia nukleiinihappoja ja niiden käyttö FI116850B (fi)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US78370791A 1991-10-25 1991-10-25
US78370791 1991-10-25
US80572391A 1991-12-05 1991-12-05
US80572391 1991-12-05
PCT/US1992/008990 WO1993008207A1 (en) 1991-10-25 1992-10-23 Novel cytokine
US9208990 1992-10-23

Publications (3)

Publication Number Publication Date
FI941837A0 FI941837A0 (fi) 1994-04-20
FI941837A true FI941837A (fi) 1994-05-30
FI116850B FI116850B (fi) 2006-03-15

Family

ID=27120174

Family Applications (2)

Application Number Title Priority Date Filing Date
FI941837A FI116850B (fi) 1991-10-25 1994-04-20 CD40-L-polypeptidiä koodaavia nukleiinihappoja ja niiden käyttö
FI981765A FI116828B (fi) 1991-10-25 1998-08-17 Menetelmä vasta-aineiden valmistamiseksi, jotka ovat immunoreaktiivisia CD40-L-proteiinin kanssa

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI981765A FI116828B (fi) 1991-10-25 1998-08-17 Menetelmä vasta-aineiden valmistamiseksi, jotka ovat immunoreaktiivisia CD40-L-proteiinin kanssa

Country Status (13)

Country Link
EP (2) EP0667901B2 (fi)
JP (2) JP3308534B2 (fi)
KR (1) KR100283541B1 (fi)
AT (2) ATE239790T1 (fi)
AU (1) AU661360B2 (fi)
CA (2) CA2121798C (fi)
DE (2) DE69233402T3 (fi)
DK (3) DK0897983T3 (fi)
ES (2) ES2198025T3 (fi)
FI (2) FI116850B (fi)
HK (1) HK1019343A1 (fi)
NO (2) NO317625B1 (fi)
WO (1) WO1993008207A1 (fi)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716805A (en) * 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US5981724A (en) * 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
US7405270B2 (en) 1991-10-25 2008-07-29 Immunex Corporation CD40-Ligand lacking native-pattern glycosylation
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US7070777B1 (en) * 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US6472510B1 (en) 1992-02-14 2002-10-29 Bristol-Myers Squibb Company CD40 receptor ligands
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5874082A (en) * 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
WO1994004570A1 (en) * 1992-08-21 1994-03-03 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
ATE256180T1 (de) * 1993-01-22 2003-12-15 Immunex Corp Detektion und behandlung von mutationen in einem gen für einen cd40-liganden
AU676227B2 (en) * 1993-01-22 1997-03-06 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Therapeutic agent for NIDDM
DK0742721T3 (da) * 1993-09-02 1999-11-01 Dartmouth College Fremgangsmåder til forlænget suppression af humoral immunitet
DK0721346T3 (da) * 1993-09-02 1999-03-22 Dartmouth College Fremgangsmåde til induktion af antigenspecifik T-celletolerance
US5869049A (en) * 1993-09-02 1999-02-09 Trustees Of Dartmouth College Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists
KR100398819B1 (ko) * 1993-09-02 2004-02-05 트러스티스 오브 다트마우스 칼리지 gp39길항제를포함하는약제조성물
WO1995014487A1 (en) * 1993-11-24 1995-06-01 The Australian National University Treatment of viral disease with cd40l peptide
WO1995017202A1 (en) * 1993-12-23 1995-06-29 Immunex Corporation Method of preventing or treating disease characterized by neoplastic cells expressing cd40
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
JP3881691B2 (ja) 1994-04-28 2007-02-14 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド Ｂ細胞の増殖方法及び分化方法並びにその使用
EP0812206B1 (en) * 1995-03-01 2002-07-10 Immunex Corporation Cd40 binding protein for stimulating an immune response
WO1996028568A1 (en) 1995-03-13 1996-09-19 The Regents Of The University Of Michigan Cd40 binding compositions and methods of using same
PT832229E (pt) * 1995-06-07 2004-06-30 Immunex Corp Muteina de cd40l
JPH11508262A (ja) * 1995-06-22 1999-07-21 バイオジェン，インコーポレイテッド Ｃｄ４０リガンドのフラグメントの結晶およびその使用
US6440418B1 (en) 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
EP0910474B1 (en) * 1996-06-14 2004-03-24 University of Washington Absorption-enhanced differential extraction method
EP0961824A4 (en) * 1996-07-10 2003-01-29 Immunex Corp METHOD FOR ACTIVATING DENTRITIC CELLS
US6017527A (en) * 1996-07-10 2000-01-25 Immunex Corporation Activated dendritic cells and methods for their activation
US7070771B1 (en) 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
DE122010000048I1 (de) 1996-12-23 2011-05-05 Immunex Corp Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
ATE412746T1 (de) 1998-05-14 2008-11-15 Immunex Corp Verfahren zur hemmung der wirkung der osteoklasten
IL142023A0 (en) 1998-10-23 2002-03-10 Amgen Inc Dimeric thrombopoietin peptide mimetics binding to mpi receptor and having thrombopoietic activity
US7300774B1 (en) 1999-12-09 2007-11-27 The Regents Of The University Of California Multimeric fusion proteins of the TNF superfamily ligands
EP1067194A1 (en) * 1999-04-16 2001-01-10 F. Hoffmann-La Roche Ag Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof
AR023482A1 (es) * 1999-04-16 2002-09-04 Hoffmann La Roche Acidos nucleicos que codifican polipeptidos quimericos cd40/cd4ol, metodos para su produccion y usos de los mismos
WO2001016180A2 (en) * 1999-08-27 2001-03-08 Board Of Regents, The University Of Texas System Cd40 agonist compositions and methods of use
GB9927757D0 (en) * 1999-11-25 2000-01-26 Kennedy Rheumatology Inst Treatment of autoimmune diseases
WO2001079555A2 (en) 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
EP1284747A2 (en) 2000-05-12 2003-02-26 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for achieving immune suppression
DE60143535D1 (de) 2000-10-02 2011-01-05 Novartis Vaccines & Diagnostic Humane antikörper gegen cd40
WO2002036769A2 (en) * 2000-10-31 2002-05-10 F. Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
US6586245B2 (en) 2001-07-18 2003-07-01 Isis Pharmaceuticals, Inc. Antisense modulation of CD40 ligand expression
EP1414483A1 (en) * 2001-07-31 2004-05-06 Serono Genetics Institute S.A. Agonists and antagonists of moxifin for the treatment of metabolic disorders
PT1434871T (pt) 2001-09-20 2017-04-05 Immunex Corp Seleção de células que expressam polipéptidos heteroméricos
US7786282B2 (en) 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
US7495090B2 (en) 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
MXPA05008523A (es) 2003-02-14 2005-10-20 Biogen Idec Inc Un casete de expresion y vector para la expresion transitoria o estable de moleculas exogenas.
BRPI0513798A (pt) 2004-07-26 2008-05-13 Biogen Idec Inc anticorpos anti-cd154
WO2006042177A2 (en) 2004-10-07 2006-04-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
US8513008B2 (en) 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
RU2007118954A (ru) 2004-10-22 2008-11-27 Эмджен Инк. (Us) Способ рефолдинга рекомбинантных антител
EP2527425A1 (en) 2006-09-13 2012-11-28 Abbott Laboratories Cell culture improvements
EP2500415A1 (en) 2006-09-13 2012-09-19 Abbott Laboratories Cell culture improvements
MY188753A (en) 2006-09-18 2021-12-29 Univ Arkansas Compositions and methods of enhancing immune responses
EP2197911A2 (en) 2007-09-14 2010-06-23 Amgen Inc. Homogeneous antibody populations
US9125854B2 (en) 2007-10-30 2015-09-08 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to flagellated bacterium
NZ601880A (en) 2007-11-01 2013-12-20 Univ Arkansas Compositions and methods of enhancing immune responses to eimeria
JP5635912B2 (ja) 2008-01-15 2014-12-03 アッヴィ・インコーポレイテッド 改善された哺乳動物発現ベクター及びその使用
HUE035508T2 (en) 2009-11-17 2018-05-02 Squibb & Sons Llc Methods for enhanced protein production
DK2525817T3 (en) 2010-01-21 2017-10-02 Univ Arkansas Vaccine vectors and methods for enhancing immune responses
KR102008120B1 (ko) 2010-06-09 2019-08-07 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 캄필로박터 감염을 감소시키기 위한 백신 및 방법
BR112015019283B1 (pt) 2013-02-14 2023-12-19 The Board Of Trustees Of The University Of Arkansas Composições e métodos de aprimoramento de respostas imunes à eiméria ou infecção por eiméria limitadora
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
AR095313A1 (es) 2013-03-15 2015-10-07 Univ Arkansas Composiciones y métodos para aumentar la respuesta inmune contra patógenos entéricos
MX2017016844A (es) 2015-07-16 2018-08-15 Biokine Therapeutics Ltd Composiciones y procedimientos para tratar cancer.
US10669343B2 (en) 2015-08-05 2020-06-02 Janssen Biotech, Inc. Anti-CD154 antibodies and methods of using them
WO2017083604A1 (en) 2015-11-12 2017-05-18 Amgen Inc. Triazine mediated pharmacokinetic enhancement of therapeutics
MX2018013331A (es) 2016-05-03 2019-06-10 Univ Arkansas Vector de vacuna de levadura que incluye polipeptidos inmunoestimuladores y antigenicos y metodos para su uso.
AU2017263454B2 (en) 2016-05-11 2023-02-09 Amgen Inc. Direct selection of cells expressing high levels of heteromeric proteins using glutamine synthetase intragenic complementation vectors
KR102745835B1 (ko) 2017-02-27 2024-12-24 샤턱 랩스 인코포레이티드 Tigit- 및 light-기반 키메라 단백질
KR20190124247A (ko) * 2017-02-27 2019-11-04 샤턱 랩스 인코포레이티드 Csf1r-기반 키메라 단백질

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL104684A0 (en) * 1992-02-14 1993-06-10 Bristol Myers Squibb Co The cd40cr receptor and ligands therefor
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation

Also Published As

Publication number Publication date
DE69233402D1 (de) 2004-09-23
FI116850B (fi) 2006-03-15
FI981765A (fi) 1998-08-17
EP0667901A1 (en) 1995-08-23
HK1019343A1 (en) 2000-02-03
EP0897983A3 (en) 1999-03-17
DK0897983T3 (da) 2003-08-11
KR100283541B1 (ko) 2001-03-02
AU661360B2 (en) 1995-07-20
EP0897983A2 (en) 1999-02-24
ES2198025T3 (es) 2004-01-16
DE69233051T2 (de) 2004-03-11
CA2312667A1 (en) 1993-04-29
CA2121798A1 (en) 1993-04-29
AU3122693A (en) 1993-05-21
JPH10150994A (ja) 1998-06-09
NO941422D0 (no) 1994-04-19
NO941422L (fi) 1994-06-27
NO980030L (no) 1998-01-05
ATE239790T1 (de) 2003-05-15
DE69233051D1 (de) 2003-06-12
FI941837A0 (fi) 1994-04-20
FI116828B (fi) 2006-03-15
WO1993008207A1 (en) 1993-04-29
DE69233402T2 (de) 2005-09-15
DK0667901T3 (da) 2004-12-27
JP2877788B2 (ja) 1999-03-31
NO980030D0 (no) 1998-01-05
ES2227513T5 (es) 2009-04-01
DK0667901T4 (da) 2008-11-10
EP0667901B2 (en) 2008-10-15
NO317625B1 (no) 2004-11-29
ES2227513T3 (es) 2005-04-01
NO320073B1 (no) 2005-10-17
EP0667901A4 (en) 1995-06-22
ATE274055T1 (de) 2004-09-15
DK0822199T3 (da) 2004-12-27
JP3308534B2 (ja) 2002-07-29
CA2121798C (en) 2007-07-24
EP0897983B1 (en) 2003-05-07
JPH07504083A (ja) 1995-05-11
CA2312667C (en) 2002-11-19
DE69233402T3 (de) 2009-06-25
EP0667901B1 (en) 2004-08-18
FI981765A0 (fi) 1998-08-17

Similar Documents

Publication Publication Date Title
FI941837A (fi) Uusia sytokiinejä
DE68917200D1 (de) Optischer Kopf mit fliegender Linse.
DE3685004D1 (de) Intraokulare linse.
NO891080L (no) Undertrykksles av b-celler i pattedyr.
DE3773293D1 (de) Weiche intraokulare linse.
DE68923240D1 (de) Nichtabbildende Lichtquelle.
NO885347D0 (no) Lysarmatur med opplyskontroll.
DE68916079D1 (de) Intraokulare Linse.
DE3886316D1 (de) Angefügter optischer Schweibsteuerkopf.
DE3850528D1 (de) Intraokulare Linse.
DE68900533D1 (de) Optischer positionssensor.
NO890618L (no) Optisk avstandsbrannroer.
ITPN910039U1 (it) Lavastoviglie con sistema di asciugatura a condensazione
DE3885075D1 (de) Antriebsanordnung einer objektivlinse.
DE68917796D1 (de) Intraokulare Linse.
DE3765979D1 (de) Intraokulare linse mit verminderter blendwirkung.
DE3874403D1 (de) Lichtventil-projektor mit erhoehter lichtausbeute.
DE3783793D1 (de) Lichtventilprojektor mit einer verbesserten schlitzblende.
ATE98761T1 (de) Laermisolierung mit lichtreflektierender oberflaeche.
IT224627Z2 (it) Cambio di velocita', meccanico.
NO910287L (no) Flerfokal intraokulaer linse.
DK349787D0 (da) 1,2,3-thiadiazol-4-thiolater samt n3-thioacylsemicarbazider
IT8122142V0 (it) Interruttore e variatore di intensita' comandabile a mano nonche' a distanza, asservito ad un mezzo di illuminazione.
ATE63690T1 (de) Innenaugenlinse mit verbesserter oberflaeche.
FI890457A0 (fi) Ledare foer eldstad och eldstadsvaegg foersedd med flera ledare.

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 116850

Country of ref document: FI